November 18, 2026
Health news, explained with evidence
LIVE

CDC Reports One in Ten U.S. Adults Used GLP-1 Medications Over the Past Year

🧠 AI Analysis 2 min read 👁 4

A recent CDC report reveals widespread U.S. adoption of GLP-1 drugs alongside significant reliance on compounded alternatives and altered dosing due to cost.

CDC Reports One in Ten U.S. Adults Used GLP-1 Medications Over the Past Year🧠AI Analysis

Photo: statnews.com

Key points

  • Roughly 10% of U.S. adults used a GLP-1 drug in the past year, per CDC data.
  • About 20% of users took compounded versions, and 9% were unsure of FDA approval status.
  • Cost and availability led roughly 40% of users to modify their prescribed usage.

A recent report published by the Centers for Disease Control and Prevention indicates that roughly one in ten adults in the United States used a GLP-1 medication over the prior year during July and August 2025. The findings highlight significant public interest in these treatments, which have gained substantial traction for managing weight and metabolic health.

However, the survey data also point to notable safety and adherence concerns among consumers. Approximately one in five individuals taking a GLP-1 drug reported using a compounded formulation, while nearly one in ten remained unsure whether their medication was officially approved by the U.S. Food and Drug Administration. Furthermore, about two out of five users altered their medication regimens contrary to their original prescriptions, frequently pointing to financial barriers and product availability as primary drivers for these modifications.

These observational findings underscore ongoing challenges regarding medication access, affordability, and consumer awareness surrounding unverified or compounded alternatives. Patients considering these therapies should consult qualified healthcare professionals to discuss safe treatment options and personal health decisions. What to know: Approximately 10% of U.S. adults used GLP-1 medications recently, with many altering doses or unknowingly taking compounded versions due to cost and availability hurdles.

Source statnews.com — statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.